seed
Stage
About
P3 Therapeutics develops first-in-class small chemical molecules using a Triple Target Activation approach to treat chronic immune-mediated inflammatory diseases such as spondyloarthritis, combining AI/ML drug discovery with organ-on-chip biomarker platforms for preclinical testing and offering collaborations and licensing.
Explore P3 Therapeutics (P3T)'s full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.